Alan B. Lancz & Associates’s Hologic HOLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,450
| Closed | -$261K | – | 142 |
|
|
2026
Q1 | $261K | Sell |
3,450
-850
| -20% | -$63.9K | 0.25% | 110 |
|
|
2025
Q4 | $320K | Sell |
4,300
-150
| -3% | -$11K | 0.28% | 87 |
|
|
2025
Q3 | $300K | Hold |
4,450
| – | – | 0.27% | 97 |
|
|
2025
Q2 | $290K | Hold |
4,450
| – | – | 0.29% | 91 |
|
|
2025
Q1 | $275K | Hold |
4,450
| – | – | 0.29% | 93 |
|
|
2024
Q4 | $321K | Sell |
4,450
-500
| -10% | -$39.1K | 0.33% | 83 |
|
|
2024
Q3 | $403K | Hold |
4,950
| – | – | 0.37% | 74 |
|
|
2024
Q2 | $368K | Buy |
+4,950
| New | +$371K | 0.36% | 74 |
|
|
2023
Q4 | $361K | Hold |
5,050
| – | – | 0.38% | 78 |
|
|
2023
Q3 | $350K | Hold |
5,050
| – | – | 0.4% | 77 |
|
|
2023
Q2 | $409K | Hold |
5,050
| – | – | 0.44% | 72 |
|
|
2023
Q1 | $408K | Hold |
5,050
| – | – | 0.42% | 70 |
|
|
2022
Q4 | $404K | Sell |
5,050
-200
| -4% | -$14.2K | 0.41% | 78 |
|
|
2022
Q3 | $339K | Sell |
5,250
-650
| -11% | -$45K | 0.4% | 76 |
|
|
2022
Q2 | $421K | Sell |
5,900
-550
| -9% | -$40.8K | 0.42% | 66 |
|
|
2022
Q1 | $495K | Sell |
6,450
-400
| -6% | -$28.8K | 0.44% | 69 |
|
|
2021
Q4 | $524K | Buy |
+6,850
| New | +$504K | 0.46% | 63 |
|
Other funds holding HOLX
Alan B. Lancz & Associates's HOLX Position: Q2 2026 in Review
Alan B. Lancz & Associates sold out of Hologic (HOLX) in Q2 2026, closing a stake of 3,450 shares — an estimated $261K sold.
Alan B. Lancz & Associates first reported a position in HOLX in Q4 2021 and held it in 17 quarters. The position peaked at $524K in Q4 2021. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.
- Alan B. Lancz & Associates reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
- Alan B. Lancz & Associates sold 3,450 Hologic shares in Q2 2026, an estimated $261K.
- Alan B. Lancz & Associates first reported a position in Hologic in Q4 2021 and held it in 17 quarters.
- Alan B. Lancz & Associates's Hologic position peaked at $524K in Q4 2021.
- 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.
Based on Alan B. Lancz & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.